The role of prognostic factors and inflammatory markers in identifying lymph node metastases of cutaneous malignant melanoma
Öz
Purpose: Malignant melanomas have poor prognosis and comprise a significant part of skin cancer-related mortality. Lymph node metastases significantly reduce survival independent of other factors. This study sought to identify factors associated with lymphatic metastasis in patients with cutaneous malignant melanoma (CMM). Materials and Methods: Histopathological and clinical prognostic factors, tumor location, inflammatory markers, and Tumor Volume Index (TVI = Breslow thickness × tumor size) were examined in patients operated for CMM in a university hospital between 2012 and 2025. Results: The study included a total of 56 patients with CMM, 50% (n=28) of whom were female. Of the 33 patients (58.9%) who underwent lymph node sampling, metastasis was detected in 34.4% (n=11). Among patients with lymph node metastasis, CMM was located more frequently in the lower extremities and less frequently in the trunk/upper extremities compared to those without lymph node metastasis. A platelet-to-lymphocyte ratio (PLR) cut-off value of 127 was statistically significant in the prediction of lymph node metastasis risk. A PLR of 127 or higher was associated with 5.3 times higher odds of detecting lymph node metastasis. However, TVI ≥27 was an independent risk factor associated with 11.1 times higher odds of lymph node metastasis (95% CI: 1.123-109.494). Conclusion: When the Breslow thickness is multiplied by the tumor's largest measured diameter, a TVI value greater than 27 has been found to be an independent risk factor for the development of lymph node metastasis.
Anahtar Kelimeler
Prognostic factor, inflammatory markers, lymph node metastases, cutaneous malignant melanoma
Proje Numarası
Etik Beyan
Teşekkür
Kaynakça
- Xavier MHSB, Drummond-Lage AP, Baeta C, Rocha L, Almeida AM, Wainstein AJA. Delay in cutaneous melanoma diagnosis: sequence analyses from suspicion to diagnosis in 211 patients. Medicine. 2016;95:e4396.
- Reintgen DS, Rapaport DP, Tanabe KK, Ross MI. Lymphatic mapping and sentinel lymphadenectomy. In Cutaneous Melanoma. 3rd ed. (Eds CM Balch, AN Houghton, AJ Sober, SJ Soong):227-44. St. Louis: Quality Medical Publishing; 1998.
- Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S et al E. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med. 2000;41:1491-4.
- Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDGP sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol. 2001;77:237-42.
- Cheng D, McNicoll CF, Kirgan D, Jones MS, Rivera MR, Doyle GM et al. The role of FDG-PET-CT is limited in initial staging of nodal metastasis for thin cutaneous melanoma. Am J Surg. 2021;221:737-40.
- Huang H, Fu Z, Ji J, Huang J, Long X. Predictive values of pathological and clinical risk factors for positivity of sentinel lymph node biopsy in thin melanoma: a systematic review and meta-analysis. Front Oncol. 2022;12:817510.
- Vița O, Jurescu A, Văduva A, Cornea R, Cornianu M, Tăban S et al. Invasive cutaneous melanoma: evaluating the prognostic significance of some parameters associated with lymph node metastases. Medicina (Kaunas). 2023;59:1241.
- Liu J, Lin PC, Zhou BP. Inflammation fuels tumor progress and metastasis. Curr Pharm Des. 2015;21:3032-40.
- Altan M, Haberal HB, Akdoğan B, Özen B. A critical prognostic analysis of neutrophil–lymphocyte ratio for patients undergoing nephroureterectomy due to upper urinary tract urothelial carcinoma. Int J Clin Oncol. 2017;22:964–71.
- Wade RG, Robinson AV, Lo MC, Keeble C, Marples M, Dewar DJ et al. Baseline neutrophil–lymphocyte and platelet–lymphocyte ratios as biomarkers of survival in cutaneous melanoma: a multicenter cohort study. Ann Surg Oncol. 2018;25:3341-9.
